tiprankstipranks
Trending News
More News >
Buy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
PremiumRatingsBuy Rating for Akero Therapeutics Driven by EFX’s Promising Position in MASH Treatment and Market Potential
1M ago
3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 5/27/2025, According to Top Analysts
1M ago
Akero Therapeutics price target raised to $64 from $63 at BofA
Premium
The Fly
Akero Therapeutics price target raised to $64 from $63 at BofA
1M ago
Akero Therapeutics price target lowered to $78 from $80 at Citi
PremiumThe FlyAkero Therapeutics price target lowered to $78 from $80 at Citi
2M ago
Akero Therapeutics Advances in MASH Treatment Research
Premium
Company Announcements
Akero Therapeutics Advances in MASH Treatment Research
2M ago
Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley
Premium
The Fly
Akero Therapeutics price target lowered to $84 from $90 at Morgan Stanley
2M ago
Promising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
PremiumRatingsPromising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
2M ago
Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
Premium
The Fly
Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
2M ago
Akero Therapeutics announces publication of Phase 2b SYMMETRY trial
Premium
The Fly
Akero Therapeutics announces publication of Phase 2b SYMMETRY trial
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100